Tetagam P Dosage/Direction for Use

Children and adults are to receive the same dose.
Prophylaxis of Tetanus Prone Wounds: 250 IU unless the risk is thought to be extremely high.
The dose may be increased to 500 IU in case of: Infected wounds where surgically appropriate treatment cannot be achieved within 24 hours; deep or contaminated wounds with tissue damage and reduced oxygen supply, as well as foreign-body injury (e.g., bites, stings or shots); burns, congelations; tissue necrosis; septicaemic abortion; adults weighing more than the average.
In case of extensive burns it is advisable to administer a second injection of 250 IU Human Tetanus Immunoglobulin (Tetagam P) after the exudative phase of the burn has subsided (about 36 hours after onset of the burn).
Therapy of Clinically Manifest Tetanus: Single doses of 3,000 to 6,000 IU (in combination with other appropriate clinical procedures). Regarding frequency, interval of injection and duration of therapy repeated doses depend on the clinical picture.
Method of administration: Human Tetanus Immunoglobulin (Tetagam P) should be administered via the intramuscular route.
Do not use solutions which are cloudy or contain residues (deposits/particles).
Human Tetanus Immunoglobulin (Tetagam P) is a ready for use solution and should be administered at body temperature.
If comparatively large total volumes are required, it is advisable to administer them in divided doses at different sites. This applies in the case of doses above 2 ml for children up to 20 kg bw and doses above 5 ml for persons above 20 kg bw.
In case of simultaneous vaccination the immunoglobulin and the vaccine should be administered at contralateral sites of the body.
In the presence of a severe coagulation disorder, in the case of which intramuscular injections are contraindicated, Human Tetanus Immunoglobulin (Tetagam P) may be given subcutaneously (under the skin) for prophylaxis. Afterwards the injection site should be compressed with a swab. However, it should be noted that there are no clinical efficacy data to support administration by the subcutaneous route.
For acute therapy, if intramuscular administration is not clinically appropriate, an alternative intravenous product may be used.
If the patient has any further questions on the use of this product, ask the doctor or pharmacist.